Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zevotrelvir
- Development stage
- Phase 2
- Lead developer
- Enanta Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Zevotrelvir is an orally administered small-molecule inhibitor of the SARS-CoV-2 main protease (Mpro, also known as 3CL protease), developed by Enanta Pharmaceuticals as a direct-acting antiviral for the treatment of COVID-19. It is a non-covalent, nanomolar 3CLpro inhibitor with a spirocyclic indole-based scaffold that selectively targets the viral protease essential for processing the SARS-CoV-2 polyproteins, thereby blocking viral replication with broad activity against human coronaviruses in biochemical assays.[1][4][5][7][9][11][13][15]
- Other names
- zevotrelvirEDP-235EDP235EDP 235
02
Targets
Mpro (3C-like proteinase of SARS-CoV-2)
Beyond the preview
Go deeper on zevotrelvir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zevotrelvir.